Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
Authors:
- Rosalba TorrisiRTRosalba Torrisi
- Raffaella PalumboRPRaffaella Palumbo
- Rita De SanctisRita De Sanctis
- Patrizia ViciPVPatrizia Vici
- Laura CortesiLCLaura Cortesi
- Vita LeonardiVLVita Leonardi
- Rossana GueliRGRossana Gueli
- Alessandra FabiAFAlessandra Fabi
- Maria Rosaria ValerioMVMaria Rosaria Valerio
- Barbara TagliaferriBTBarbara Tagliaferri
- 27 August 2021
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 190 (1) , 103-109
Abstract
Purpose The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3rd line in 67 patients. Among the 86 evaluable patients, 6 (6.9%) achieved CR, 18 (20.7%) PR, and 44 (50.6%) had SD ≥ 24 weeks with an overall CBR of 78.2%. At a median follow-up of 33.6 months, mPFS of the entire cohort was 12.9 months (range, 2.47–128.67). No difference was observed in mPFS between patients treated after progression or as maintenance therapy (mPFS 12.9 and 13.9 months in 64 and 23 patients, respectively), neither considering the number of previous treatment lines (≤ 3 or < 3). Conclusion The combination of F and T was active in this cohort at poor prognosis and deserves further investigations possibly in combination with pertuzumab in patients with high ER expression.Keywords
This publication has 32 references indexed in Scilit:
- Co-targeting estrogen receptor and HER2 pathways in breast cancerThe Breast, 2014
- First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHERThe Oncologist, 2013
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Hormone‐receptor expression and activity of trastuzumab with chemotherapy in HER2‐positive advanced breast cancer patientsCancer, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyJournal of Clinical Oncology, 2009
- Activity of fulvestrant in HER2-overexpressing advanced breast cancerAnnals of Oncology, 2009
- Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant TreatmentClinical Cancer Research, 2007
- Fulvestrant (Faslodex®)—How to Make a Good Drug BetterThe Oncologist, 2007